Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program Acurx Pharmaceuticals has unveiled a new clinical trial program for Ibezapolstat targeting recurrent CDI, aiming to transform treatment standards and efficacy.

Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program #United_States #Ibezapolstat #Staten_Island #Acurx_Pharmaceuticals #CDI_Treatment